Identification of proteomic biomarkers associated with eplerenone treatment versus spironolactone in post-acute coronary syndrome patients, with non-controlled arterial hypertension and ventricular dysfunction [Evaluacion mediante proteomica de biomarcadores proteicos asociados con el tratamiento con Eplerenona versus espironolactona en pacientes post-infarto agudo de miocardio, diabeticos con hipertension arterial no controlada y disfuncion ventricular sistolica leve]
Latest Information Update: 12 Jul 2011
Price :
$35 *
At a glance
- Drugs Eplerenone (Primary) ; Spironolactone
- Indications Heart failure; Hypertension; Ventricular dysfunction
- Focus Biomarker; Pharmacodynamics
- Acronyms PROMETEO
- 12 Jul 2011 New trial record